Serum angiopoietin‐2 levels predict regression of Mac‐2 binding protein glycosylation isomer‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents

Aim It is desirable to identify predictors of regression of liver fibrosis after achieving a sustained virologic response (SVR) by direct‐acting antiviral agents (DAAs) to antihepatitis C virus (HCV) therapy. Here, we retrospectively investigated the serum angiopoietin‐2 (Ang‐2) level as a predictive indicator of regression of liver fibrosis after successful HCV eradication by DAA therapy. Methods The study subjects were recruited from a historical cohort of 109 chronically HCV‐infected patients who had achieved SVR by DAA therapy and whose serum Mac‐2 binding protein glycosylation isomer (M2BPGi) levels at baseline (before DAA therapy) were ≥2.0 the cut‐off index (COI). We defined patients with M2BPGi levels